JP5993875B2 - 縮合アミノジヒドロチアジン誘導体の合成に有用な方法および化合物 - Google Patents

縮合アミノジヒドロチアジン誘導体の合成に有用な方法および化合物 Download PDF

Info

Publication number
JP5993875B2
JP5993875B2 JP2013550622A JP2013550622A JP5993875B2 JP 5993875 B2 JP5993875 B2 JP 5993875B2 JP 2013550622 A JP2013550622 A JP 2013550622A JP 2013550622 A JP2013550622 A JP 2013550622A JP 5993875 B2 JP5993875 B2 JP 5993875B2
Authority
JP
Japan
Prior art keywords
compound
mixture
formula
added
vol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013550622A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503001A5 (OSRAM
JP2014503001A (ja
Inventor
ミタセフ,ブランコ
キム,デシク
チャン,フイミン
シュナダーベック,マシュー・ジェイ
ファージング,クリストファー・エヌ
一洋 吉澤
一洋 吉澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2014503001A publication Critical patent/JP2014503001A/ja
Publication of JP2014503001A5 publication Critical patent/JP2014503001A5/ja
Application granted granted Critical
Publication of JP5993875B2 publication Critical patent/JP5993875B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2013550622A 2011-01-21 2012-01-20 縮合アミノジヒドロチアジン誘導体の合成に有用な方法および化合物 Expired - Fee Related JP5993875B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161434849P 2011-01-21 2011-01-21
US61/434,849 2011-01-21
PCT/US2012/022053 WO2012100179A1 (en) 2011-01-21 2012-01-20 Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016041508A Division JP6087005B2 (ja) 2011-01-21 2016-03-03 縮合アミノジヒドロチアジン誘導体の合成に有用な方法および化合物

Publications (3)

Publication Number Publication Date
JP2014503001A JP2014503001A (ja) 2014-02-06
JP2014503001A5 JP2014503001A5 (OSRAM) 2016-01-28
JP5993875B2 true JP5993875B2 (ja) 2016-09-14

Family

ID=45563570

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013550622A Expired - Fee Related JP5993875B2 (ja) 2011-01-21 2012-01-20 縮合アミノジヒドロチアジン誘導体の合成に有用な方法および化合物
JP2016041508A Expired - Fee Related JP6087005B2 (ja) 2011-01-21 2016-03-03 縮合アミノジヒドロチアジン誘導体の合成に有用な方法および化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016041508A Expired - Fee Related JP6087005B2 (ja) 2011-01-21 2016-03-03 縮合アミノジヒドロチアジン誘導体の合成に有用な方法および化合物

Country Status (12)

Country Link
US (3) US8426584B2 (OSRAM)
EP (1) EP2665716B1 (OSRAM)
JP (2) JP5993875B2 (OSRAM)
CN (2) CN103502231A (OSRAM)
BR (1) BR112013016241A2 (OSRAM)
CA (1) CA2814014A1 (OSRAM)
ES (1) ES2624288T3 (OSRAM)
IL (1) IL226405A0 (OSRAM)
MX (1) MX2013005115A (OSRAM)
RU (1) RU2013138226A (OSRAM)
SG (2) SG191710A1 (OSRAM)
WO (1) WO2012100179A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317850A1 (en) 2008-01-18 2010-12-16 Yuichi Suzuki Condensed aminodihydrothiazine derivative
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
GB201212816D0 (en) * 2012-07-19 2012-09-05 Eisai Ltd Novel compounds
TWI639607B (zh) 2013-06-18 2018-11-01 美國禮來大藥廠 Bace抑制劑
CA2963761C (en) * 2014-10-10 2023-10-17 Eisai R&D Management Co., Ltd. Pharmaceutical composition of fused aminodihydrothiazine derivative
IL316169A (en) 2016-10-27 2024-12-01 Eisai R&D Man Co Ltd Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease
CA3107370A1 (en) 2018-07-24 2020-01-30 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235551A (en) 1966-02-15 Novel derivatives of
US3227713A (en) 1966-01-04 Azine derivatives
JPH0967355A (ja) 1995-08-31 1997-03-11 Tokyo Tanabe Co Ltd チアジン誘導体、チアゾール誘導体及びそれらの製造方法
US20040110743A1 (en) 2000-05-19 2004-06-10 Masaomi Miyamato -Secretase inhibitors
US6562783B2 (en) 2001-05-30 2003-05-13 Neurologic, Inc. Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors
AU2003254844A1 (en) 2002-08-09 2004-02-25 Takeda Chemical Industries, Ltd. Substituted amino compounds and use thereof
WO2004037212A2 (en) 2002-10-24 2004-05-06 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
JP2004149429A (ja) 2002-10-29 2004-05-27 Takeda Chem Ind Ltd インドール化合物およびその用途
WO2004043916A1 (en) 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
NZ547462A (en) 2003-12-15 2010-06-25 Schering Corp Heterocyclic aspartyl protease inhibitors
US20070203147A1 (en) 2004-03-30 2007-08-30 Coburn Craig A 2-Aminothiazole Compounds Useful As Aspartyl Protease Inhibitors
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
EP1802587A4 (en) 2004-10-15 2010-02-17 Astrazeneca Ab SUBSTITUTED AMINO BINDINGS AND THEIR APPLICATIONS
WO2006041405A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-pyrimidones and uses thereof
AU2006206654A1 (en) 2005-01-19 2006-07-27 Merck & Co., Inc. Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of Alzheimer's disease
CA2609582A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
AU2006270084B2 (en) 2005-07-18 2011-08-25 Merck Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
US8173642B2 (en) 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
CN101460480A (zh) 2006-04-05 2009-06-17 阿斯利康(瑞典)有限公司 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途
US8049006B2 (en) 2006-05-31 2011-11-01 Daiichi Sankyo Company, Limited 7-membered ring compound and method of production and pharmaceutical application thereof
CA2672293A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
EP2151435A4 (en) * 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
MX2009011498A (es) 2007-04-24 2009-11-10 Shionogi & Co Derivados de aminodihidrotiazina sustituida con un grupo ciclico.
PL2151436T3 (pl) 2007-05-29 2013-09-30 Santen Pharmaceutical Co Ltd Nowe pochodne 1,2,3,4-tetrahydrochinoksaliny, które jako podstawnik zawierają grupę fenylową z wprowadzoną strukturą estru kwasu sulfonowego lub amidu kwasu sulfonowego i które mają aktywność wiążącą wobec receptora glukokortykoidowego
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
US20100317850A1 (en) 2008-01-18 2010-12-16 Yuichi Suzuki Condensed aminodihydrothiazine derivative
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Bace抑制劑
KR20110048491A (ko) 2008-07-28 2011-05-11 에자이 알앤드디 매니지먼트 가부시키가이샤 스피로아미노디하이드로티아진 유도체들
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
ES2539859T3 (es) 2008-09-30 2015-07-06 Eisai R&D Management Co., Ltd. Nuevo derivado de aminodihidrotiazina condensado
AR077277A1 (es) * 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
US20130085131A1 (en) 2010-07-01 2013-04-04 Amgen Inc. Heterocyclic compounds and their uses
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives

Also Published As

Publication number Publication date
JP2016121177A (ja) 2016-07-07
CA2814014A1 (en) 2012-07-26
US8802871B2 (en) 2014-08-12
SG10201601516QA (en) 2016-03-30
CN106632401B (zh) 2020-12-29
JP6087005B2 (ja) 2017-03-01
BR112013016241A2 (pt) 2016-07-12
US8426584B2 (en) 2013-04-23
IL226405A0 (en) 2013-07-31
US20120190848A1 (en) 2012-07-26
CN103502231A (zh) 2014-01-08
MX2013005115A (es) 2013-06-03
SG191710A1 (en) 2013-08-30
US20130197244A1 (en) 2013-08-01
WO2012100179A1 (en) 2012-07-26
EP2665716A1 (en) 2013-11-27
ES2624288T3 (es) 2017-07-13
US8962858B2 (en) 2015-02-24
RU2013138226A (ru) 2015-02-27
US20140309429A1 (en) 2014-10-16
JP2014503001A (ja) 2014-02-06
EP2665716B1 (en) 2017-03-08
CN106632401A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
JP6087005B2 (ja) 縮合アミノジヒドロチアジン誘導体の合成に有用な方法および化合物
RU2476431C2 (ru) Конденсированное производное аминодигидротиазина
AU2015301028B2 (en) Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
WO2012162330A1 (en) Tricyclic compounds as inhibitors for the production of beta-amyloid
EP2935256A1 (en) 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production
EA026004B1 (ru) 5-АМИНО[1,4]ТИАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКРЕТАЗЫ 1
CA3056076A1 (en) A substituted-heterocyclic-c(o)o-(substituted pyridin-3-yl)compound and its use as a dual magl and faah inhibitor
CA3237721A1 (en) Sulfonamide compounds for the treatment of neurological conditions
US20230416252A1 (en) Process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one
RU2734475C2 (ru) Разделение энантиомеров 3-этилбицикло [3.2.0] гепт-3-ен-6-она
EP2324009A1 (en) Process for preparing certain cinnamide compounds
WO2014068341A2 (en) Chiral fluorinating reagents
WO2014015125A1 (en) Fused aminodihydrothiazine derivative salts and uses thereof
US20250188079A1 (en) Inhibiting cyclic amp-responsive element-binding protein (creb)
GB2504615A (en) Fused aminodihydrothiazine derivatives
JP2025124692A (ja) 神経障害の治療に使用するための化合物
KR20170043581A (ko) 2,2,2-트라이플루오로에틸-티아다이아진

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150116

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20150911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150911

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20151028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151207

AA91 Notification that invitation to amend document was cancelled

Free format text: JAPANESE INTERMEDIATE CODE: A971091

Effective date: 20151215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160628

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160711

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160729

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160822

R150 Certificate of patent or registration of utility model

Ref document number: 5993875

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees